Participants 674 813 7
patients with locally advanced or metastatic NSCLC who were eligible for bevacizumab, excluding those with predominantly squamous histology
Participants 1167 1202 4
1967 patients with first-line NSCLC
Participants 1274 1311 5
Median age was 65 years (range, 31-93
Participants 1318 1366 5
252 patients (12.8%) identified as never smokers
